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Cytosolic PCNA interacts with p47phox and controls
NADPH oxidase NOX2 activation in neutrophils
Delphine Ohayon1,2*, Alessia De Chiara1,2*, Pham My-Chan Dang2,3, Nathalie Thieblemont1,2, Simon Chatfield1,2, Viviana Marzaioli2,3,
Sabrina Sofia Burgener4,5, Julie Mocek1,2, Ce´line Candalh1,2, Coralie Pintard2,3, Pascale Tacnet-Delorme6, Gilles Renault1,2, Isabelle Lagoutte1,2,
Maryline Favier1,2, Francine Walker7, Margarita Hurtado-Nedelec2,3, Dominique Desplancq8, Etienne Weiss8, Charaf Benarafa4,5,
Dominique Housset6, Jean-Claude Marie2,3, Philippe Frachet6, Jamel El-Benna2,3, and Ve´ronique Witko-Sarsat1,2
Neutrophils produce high levels of reactive oxygen species (ROS) by NADPH oxidase that are crucial for host defense but can
lead to tissue injury when produced in excess. We previously described that proliferating cell nuclear antigen (PCNA), a nuclear
scaffolding protein pivotal in DNA synthesis, controls neutrophil survival through its cytosolic association with procaspases.
We herein showed that PCNA associated with p47phox, a key subunit of NADPH oxidase, and that this association regulated
ROS production. Surface plasmon resonance and crystallography techniques demonstrated that the interdomain-connecting
loop of PCNA interacted directly with the phox homology (PX) domain of the p47phox. PCNA inhibition by competing
peptides or by T2AA, a small-molecule PCNA inhibitor, decreased NADPH oxidase activation in vitro. Furthermore, T2AA
provided a therapeutic benefit in mice during trinitro-benzene-sulfonic acid (TNBS)–induced colitis by decreasing oxidative
stress, accelerating mucosal repair, and promoting the resolution of inflammation. Our data suggest that targeting PCNA in
inflammatory neutrophils holds promise as a multifaceted antiinflammatory strategy.
Introduction
Neutrophils are key cells of the innate immune system
(Mantovani et al., 2011) but may also be involved in pathological
inflammatory processes when their activation and elimination
are not properly regulated (Soehnlein et al., 2017). At sites of
inflammation, neutrophils release biological molecules includ-
ing proteases and ROS that can kill pathogens but also cause host
tissue damage (Nauseef, 2007). The enzyme responsible for ROS
production in neutrophils is the phagocyte NADPH oxidase
(NOX2), a complex composed of two membrane proteins
(gp91phox, p22phox) and four cytosolic proteins (p47phox,
p67phox, p40phox, and the small GTPase Rac1/2) that assemble
upon activation (El-Benna et al., 2016). Although ROS produc-
tion is important for innate immunity, excessive ROS release
can induce oxidative stress, leading to cell death and tissue in-
jury (Nathan and Cunningham-Bussel, 2013). ROS are involved
in numerous inflammatory diseases such as rheumatoid
arthritis, inflammatory bowel disease, atherosclerosis, and aging
(Lambeth et al., 2008). Coordination between neutrophil acti-
vation, ROS production, and cell death is pivotal in both host
defense and the control of inflammation (Kennedy and DeLeo,
2009; Geering and Simon, 2011).
In this context, we have previously shown that the prolifer-
ating cell nuclear antigen (PCNA) protein plays a key role in
neutrophil apoptosis (Witko-Sarsat et al., 2010; Ohayon et al.,
2016). In the majority of cell types, PCNA is an exclusively nu-
clear protein that regulates processes related to DNA replication
including cell cycle regulation and recombination (Maga and
Hubscher, 2003). It has been dubbed the “maestro of the repli-
cation fork” (Moldovan et al., 2007). PCNA exists as a homo-
trimer that encircles duplex DNA, forming a ring-shaped clamp.
PCNA is a trimer, and each monomer is composed of two sim-
ilarly folded globular regions linked by a flexible interdomain-
connecting loop, which is the preferred site for the binding of
partner molecules (Warbrick, 1998). PCNA is a scaffolding
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protein and has no intrinsic enzymatic activity. Reflecting the
wide variety of roles of PCNA, >100 PCNA-interacting proteins
involved in DNA-related processes have been identified (Maga
and Hubscher, 2003).
In mature neutrophils, on the other hand, PCNA is expressed
exclusively in the cytosol. PCNA is exported from the nucleus at
the end of granulocytic differentiation via a nuclear export se-
quencewe have previously identified (Bouayad et al., 2012). PCNA
dictates neutrophil survival by binding to apoptotic procaspases,
sequestering and preventing their activation (Witko-Sarsat et al.,
2010). Neutrophils are fully differentiated nonproliferative cells,
suggesting the cytosolic PCNA may coordinate functions apart
from those related to proliferation. Cytosolic PCNA also promotes
survival in acute myeloid leukemic cells resistant to chemother-
apy. Furthermore, PCNA promotes glycolysis in these cells,
serving as a scaffold for glycolytic proteins (Ohayon et al., 2016),
promoting cell functionality in addition to restraining apoptosis.
Whether PCNA has other binding partners in the cytosol of
neutrophils and what contribution PCNA makes to neutrophil
function more broadly remains poorly understood (Witko-Sarsat
and Ohayon, 2016).
Given these roles of PCNA as a scaffold, we performed an
exploratory proteomic analysis testing for novel PCNA partners
within the neutrophil cytosol. We show using a number of
techniques that PCNA associates with p47phox, a key subunit of
the NADPH oxidase complex, and that this association regulates
ROS production. Interfering with this association resulted in a
potent in vivo antiinflammatory effect in two neutrophil-
dominated models of inflammation, zymosan-induced perito-
nitis and trinitro-benzene-sulfonic acid (TNBS)–induced colitis.
Results
Cytosolic PCNA interacts with the phox homology (PX) domain
of p47phox
We identified PCNA partners by coimmunoprecipitation and
mass spectrometry (MS) analysis. PCNA was associated with
proteins involved in cytoskeleton function, oxidant regulation,
cell signaling, and glycolysis, as previously described in
HL-60 cells (Ohayon et al., 2016; Table 1). Notably, the cytosolic
components of the NADPH oxidase/NOX2, namely p47phox,
p67phox, and p40phox as well as kinases and GTP-binding
proteins, were associated with PCNA, suggesting a potential
role of PCNA in the modulation of NADPH oxidase activity. As
p47phox, p67phox, and p40phox form a complex in the cytosol,
we examined the individual in vitro interactions between
recombinant PCNA and p47phox, p67phox, p40phox, and Rac2
by surface plasmon resonance (SPR). A strong interaction was
observed between p47phox and PCNA in a dose-dependent man-
ner, with an equilibrium dissociation constant (KD) value within
the nanomolar range (KD = 7.7 × 10−8 M; Fig. 1 A and Table 2). No
direct interaction was detected between PCNA and p67phox or
p40phox, whereas Rac2 could interact with PCNA with a
micromolar-range affinity. To identify the domain of p47phox
involved in PCNA interaction, we first examined if this inter-
action could be prevented by phosphoinositides that can bind to
the PX domain (residues 1–141) that is crucial for p47phox
membrane association (Kanai et al., 2001). When phosphoino-
sitides and p47phox were preincubated before injection over
immobilized PCNA, the percentage of p47phox binding to PCNA
was decreased in a dose-dependent manner (Fig. 1 B). In keeping
with this hypothesis, recombinant PX domain generated as a
truncated p47phox protein showed a direct interaction with
PCNA, although the calculated KD was higher than that of full-
length p47phox. This suggests that either p47phox binding
is dependent on the conformation of the PX domain in intact
p47phox or other p47phox domains are involved in PCNA binding
(Fig. 1 C and Table 2).
Many PCNA-interacting proteins including p21/waf1
contain a conserved sequence known as PCNA-interacting protein
box (PIP-box) with a consensus sequence of [Q]xx[h]XX[a][a],
where h stands for hydrophobic and a for aromatic residues (Fig.
S1). We identified four peptide sequences (p47phox-46-67,
p47phox-63-90, p47phox-83-110, and p47phox-106-127) con-
taining a PIP-box motif that were not buried in p47phox PX
domain (Fig. 1 D) sequence. The corresponding p47phox peptides
were tested for their binding capacity to PCNA by SPR and were
compared with the p21-141-160-peptide used as a positive con-
trol (KD ≈ 10−7 M) and to the mutant p21 peptide deprived of
PCNA binding sites as a negative control (Zheleva et al., 2000;
Warbrick, 2006). Peptides p47phox-46-67, p47phox-63-90, and
p47phox-83-110 did not interact with PCNA, while p47phox-106-
127 showed a direct interaction with PCNA (Fig. 1 E and Table 2).
Interestingly, the p47phox-106–127 peptide and the p47phox PX
domain bind PCNA with a similar affinity (KD ≈ 5 × 10−5 M;
Table 2), strongly suggesting that the p47phox-106-127 sequence
was mainly responsible for the p47phox PX–PCNA interaction.
Coinjection of p21 peptide (2, 5, or 8 µM) with the p47phox
over immobilized PCNA decreased the binding of p47phox to
PCNA in a dose-dependent manner, compared with binding
in the absence of the p21 peptide (Fig. 1 F). Likewise, similarly to
the p21 peptide and in agreement with its ability to bind PCNA,
the p47phox-106-127 peptide inhibited the interaction between
PCNA and the p47phox protein in a dose-dependent manner, as
measured by SPR. These data unambiguously demonstrated that
the interdomain-connecting loop of PCNA was involved in the
interaction with p47phox and strongly suggested that this in-
teraction was mediated by the p47phox PX domain mapping the
106–127 residues.
To further ascertain themolecular association between PCNA
and p47phox-106-127 peptide, crystallization assays and dif-
fraction analysis were used. Crystals could be grown under
several different conditions, but one (see Materials and methods
for details) provided reproducible crystals diffracting at ∼3-A˚
resolution. The unit cell dimensions and the crystal packing
were similar for all crystals (Figs. 2 A and S1, B–D). However, the
space group was found to be either orthorhombic (P212121, one
trimer in the asymmetric unit) or monoclinic (P21, two trimers
in the asymmetric unit). Our attempts to cocrystallize intact
p47phox or its PX domain together with PCNA were unsuc-
cessful and were hampered by the flexible p47phox structure.
However, we could obtain crystallographic data by soaking
PCNA crystals in solutions containing 100–500 µM of p47phox-
106-127 peptide for 24 h before data collection. Complete
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crystallographic data were collected on ∼50 crystals, with a
maximum resolution varying from 4.2 to 2.8 A˚, and the PCNA
structure was determined for all these crystals by molecular
replacement using the PCNA 1AXC structure. In five crystals, we
observed a significant positive electron density on the residual
(Fobs − Fcalc) electron density map, indicating that the p47phox-
106-127 peptide could bind the PCNA interdomain-connecting
loop region (Fig. 2 B).
Although the maximum resolution (3.22 A˚) and the occu-
pancy of the bound peptide obtained for these five crystals was
Table 1. Proteins involved in signaling and oxidant-related processes identified by MS in the material eluted from the anti-PCNA
coimmunoprecipitation in neutrophil cytosol
Swiss-Prot ID Protein name Molecular weight Gene name UniProt ID
Ubiquitin
UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 117.8 UBA1 P22314
Cytoskeleton
PROF1_HUMAN Profilin-1 15.1 PFN1 P07737
FLNA_HUMAN Filamin-A 280.7 FLNA P21333
MOES_HUMAN Moesin 67.8 MSN P26038
VINC_HUMAN Vinculin 123.8 VCL P18206
ARC1B_HUMAN Actin-related protein 2/3 complex subunit 1B 40.9 ARPC1B O15143
Oxidant-related proteins
PDIA1_HUMAN Protein disulfide-isomerase 57.1 P4HB P07237
THIO_HUMAN Thioredoxin 11.7 TXN P10599
GTP-binding protein
IQGA1_HUMAN Ras GTPase-activating-like protein IQGAP1 189.3 IQGAP1 P46940
GDIB_HUMAN Rab GDP dissociation inhibitor β 50.7 GDI2 P50395
GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 23.2 ARHGDIA P52565
GDIR2_HUMAN Rho GDP-dissociation inhibitor 2 23 ARHGDIB P52566
NADPH oxidase
NCF1_HUMAN Neutrophil cytosol factor 1; p47phox 44.8 NCF1 P14598
NCF2_HUMAN Neutrophil cytosol factor 2; p67phox 59.8 NCF2 P19878
NCF4_HUMAN Neutrophil cytosol factor 4; p40phox 39 NCF4 Q15080
COR1A_HUMAN Coronin-1A 51 CORO1A P31146
G-coupled protein
GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit α-2 40.5 GNAI2 P04899
Glycolysis
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase 36.1 GAPDH P04406
G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase 59.3 G6PD P11413
G6PI_HUMAN Glucose-6-phosphate isomerase 63.1 GPI P06744
6PGD_HUMAN 6-Phosphogluconate dehydrogenase 53.1 PGD P52209
6PGL_HUMAN 6-Phosphogluconolactonase 27.5 PGLS O95336
ALDOA_HUMAN Fructose-bisphosphate aldolase A 39.4 ALDOA P04075
ALDOC_HUMAN Fructose-bisphosphate aldolase C 39.5 ALDOC P09972
HXK1_HUMAN Hexokinase-1 102.5 HK1 P19367
LDH6B_HUMAN L-lactate dehydrogenase A-like 6B 41.9 LDHAL6B Q9BYZ2
LDHA_HUMAN L-lactate dehydrogenase A chain 36.7 LDHA P00338
LDHB_HUMAN L-lactate dehydrogenase B chain 36.6 LDHB P07195
KPYM_HUMAN Pyruvate kinase isozymes M1/M2 57.9 PKM P14618
Immunoprecipitation of PCNA was performed in cytosols from human neutrophils obtained by nitrogen cavitation, and proteins associated with PCNA were
identified by MS. This representative experiment was performed two times on two different cytosols with similar results.
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too low to determine unambiguously the amino acids of
p47phox-106-127 involved in the interaction with PCNA, we
propose two computational models of the complex between
PCNA and p47phox PX domain, based on structures available in
the Protein Data Bank (PDB). We used the structure of the
complex between the p21 peptide (mapping the 141–160 resi-
dues) and PCNA (PDB entry 1AXC; Gulbis et al., 1996) and the
structure of the p47phox PX domain (PDB entry 1KQ6). In the
first option, structural analysis of the 1KQ6 structure showed
that the 114–118 PIP-box of p47phox was partially buried and
should adopt another conformation to be able to interact with
PCNA. Therefore, the p47phox PX-106-127 region has been
modeled to adopt a conformation close to the one adopted by p21
in 1AXC structure (Fig. 2 C). If such a mode of interaction is
plausible, as it generates no steric hindrance, it relies on a hy-
pothetical conformational change in the 106–127 region of the
p47phox PX domain that remains to be experimentally observed.
The second option was to search for regions of the p47phox PX
that adopt a conformation that is similar to the one adopted by
the p21 peptide, when bound to PCNA. The 122–126 region of the
p47phox PX domain is structurally very similar to the 147–151
region of p21 (root mean square difference of 0.25 A˚) and
corresponds to the core of the PIP-box that was structurally
conserved in numerous PCNA-peptide complex structures. By
superimposing the 122–126 residues of 1KQ6 p47phox PX
structure on the 147–151 region of 1AXC PCNA/p21 peptide, we
built a plausible PCNA-p47phox PX domain complex with no
steric clashes (Fig. 2 D). The distinction between these two
possibilities should await the crystal structure of p47phox pro-
tein, which is not yet publicly available.
PCNA is involved in NOX2 activation in intact cells
To address the functional impact of the PCNA–NOX2 interac-
tion, we first used neutrophil-like differentiated PLB985 cells, an
established model of human neutrophils, which allow transfec-
tion experiments. We previously reported that in proliferating
nondifferentiated PLB985 cells, PCNA is nuclear (Fig. 3 A) but
becomes exclusively cytosolic after differentiation, therefore
representing a suitable surrogate for human neutrophils (De
Chiara et al., 2013). Differentiated PLB985 cells that stably
overexpress PCNA as previously described (Witko-Sarsat et al.,
2010) showed a marked increase in PMA- and opsonized zy-
mosan (OZ)–induced superoxide production compared with
PLB985 cells stably transfected with control plasmid (Fig. 3, B
Figure 1. Molecular investigation of the
binding between p47phox and PCNA. (A) SPR
analysis of the interaction of p47phox (nano-
moles) over immobilized PCNA. Arrows and stars
indicate the injection start and end points for
each p47phox concentration. Fit obtained with a
statistic χ2 value 0.24 is shown as dotted line
(response units). (B) The phosphoinositide
PIP3,4,5 inhibits p47phox–PCNA interaction.
P47phox was incubated with PIP3,4,5 at various
concentrations before injection on PCNA. Bind-
ing was expressed as percentage of p47phox
binding measured without PIP3,4,5. (C) SPR
measurements of p47phox PX domain interac-
tion on PCNA. Data represent overlays of sen-
sograms resulting from injection of p47phox-PX
domain at different concentrations (micromoles).
Fits with a statistic χ2 value 1.5 are shown as
dotted lines (response units). (D) Putative PIP-
box localization within the p47phox PX domain,
shown in purple. PIP-boxes 46–67, 63–90,
83–110, and 106–127 are depicted in green, blue,
yellow, and red, respectively. The helix turn
structurally similar to p21 PIP-box is depicted in
silver. (E) Comparative binding of p21, p47phox-
46-67, p47phox-63-90, p47phox-83-110, and
p47phox-106-127 peptides on PCNA. (F) P21
peptide and p47phox-106-127 interfere with
p47phox–PCNA association measured by SPR.
The p21 peptides and p47phox-106-127 at
various concentrations were coinjected with
p47phox over PCNA as in B. Results are ex-
pressed as the percentage of p47phox binding
measured without competing peptide. SPR ex-
periments were performed three times with
identical results on either a Biacore 3000 (C–E)
or a Biacore T200 (A and B) apparatus. Kinetic
values determinations for p47/PCNA and p47-PX
domain/PCNA interactions are reported in
Table 2.
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and C). Increased PMA-induced ROS production in PCNA-
overexpressing cells was confirmed by 29,79-dichlorofluorescin
diacetate (DCF-DA) FACS analysis. Notably, this increase in
PMA-induced ROS production was abolished when PLB985 cells
were transfected with PCNA fused to the SV40 nuclear locali-
zation sequence (NLS), thereby excluding from the cytosol
(Bouayad et al., 2012; Fig. 3, D and E). Transfection of PCNA
siRNA efficiently down-regulated PCNA protein expression
(Fig. 3 F) and significantly decreased ROS production measured
by luminol chemiluminescence (CL) in response to PMA and OZ
(Fig. 3, G and H). Likewise, we used dimethylformamide (DMF)-
differentiated PLB985 cells overexpressing the protein p21/waf1
(Fig. 3 I), which can bind PCNA and inhibit its antiapoptotic
function (Martin et al., 2016). DMF-differentiated PLB985-
p21A45R cells have significantly decreased NADPH oxidase ac-
tivity triggered by either PMA or OZ relative to the PLB985 cells
expressing an empty plasmid (Fig. 3, J and K). Notably, the effect
of inhibiting PCNA on NADPH oxidase function is not merely a
consequence of loss of neutrophil viability. The decreased
NADPH oxidase function in differentiated PLB985 cells by PCNA
inhibition (by either siRNA or ectopic expression of p21/waf1)
was evident at time points in the absence of significant cell death
(Fig. S2, A and B). Altogether, these results demonstrated that
cytosolic PCNA controlled NADPH oxidase–dependent ROS
production in intact cells.
Inhibition of PCNA–p47phox interaction hindered NADPH
oxidase activation
We next examined if targeting PCNA could affect NADPH
oxidase assembly in a cell-free system consisting of the cy-
tosolic fraction containing PCNA and the NADPH oxidase
components (p47phox, p67phox, p40phox, rac2) and the
membrane fraction containing gp91phox and p22phox iso-
lated from resting human neutrophils. NADPH oxidase acti-
vation was triggered by Li-SDS and the production of
superoxide anions was measured by the cytochrome c re-
duction assay. The specificity of this assay was validated by
the inhibitory effect of superoxide dismutase (SOD) or di-
phenylene iodonium (DPI), a NADPH oxidase inhibitor (Fig. 4
A). In this cell-free system, we tested the effect of the p21
peptide (Fig. 4 B) and T2 amino alcohol (T2AA), a nonpeptide
cell-permeable PCNA inhibitor (Punchihewa et al., 2012;
Inoue et al., 2014). Both compounds bind specifically to the
PCNA interdomain-connecting loop to inhibit interactions
with its partners (Fig. 4 C). Each compound led to a dose-
dependent decrease in superoxide anion production, thereby
demonstrating that PCNA was involved in NOX2 activation.
T2AA also decreased PMA-, formyl-methionyl-leucyl phen-
ylalanine (f-MLF)–, and OZ-induced NADPH oxidase
activation in intact neutrophils measured by luminol CL in a
dose-dependent manner (Fig. 4, D–F). The inhibitory effect of
T2AA on ROS production was not related to apoptosis induc-
tion, since no Annexin-V labeling was detected on neutrophils
after 1-h T2AA treatment up to a concentration of 50 µM in
the presence of PMA (Fig. S2, C and D). Moreover, inhibition
of caspases by the pan-caspase inhibitor Z-VAD(OMe)-FMK
(Z-VAD) did not abrogate the inhibitory effect of T2AA on
f-MLF–induced respiratory burst (Fig. S2, E and F). To further
characterize the interaction between PCNA and p47phox, we
examined whether PCNA, like cytosolic NADPH oxidase
components, could translocate to the membrane upon PMA
activation. Western blot analysis of neutrophil membranes
and cytosol clearly showed that both p47phox and PCNA
translocated to the membrane fraction upon PMA activation
Table 2. Kinetics and affinity of PCNA interaction with cytosolic components of NADPH-oxidase
Immobilized ligand/soluble analyte PCNA
ka1 (M−1 s−1) kd1 (s−1) kforward (s−1) kbackward (s−1) KD (M)
p47phox (two-state model) 8.7 × 103 8.4 × 10−3 7.5 × 10−3 6.5 × 10−4 7.7 × 10−8
p47-PX domain (1:1 model) 85.2 2.8 × 10−3 NA NA 3.3 × 10−5
p47 peptide 106–127 1.0 × 104 0.35 NA NA 3.4 × 10−5 (KD1)
(Heterogeneous ligand model) 160 0.0111 NA NA 6.9 × 10−5 (KD2)
p47 peptides
83–110 ND ND ND ND ND
63–90
46–67
Rac2 (two-state model) 541 17 × 10−3 5.7 × 10−3 6.6 × 10−4 3.3 × 10−6
No significant binding was detected for p40phox and p67phox for concentrations ≤1 µM. The binding of PCNA with p47phox (25–400 nM), p47-PX domain
(1.83–29.5 µM), or p47peptide 106–127 (0.31–40 µM) was investigated by SPR as described in Materials and methods. Kinetics parameters were calculated
using either two-state, 1:1 Langmuir, or heterogeneous ligand reactions models. For the two-state binding model (A + B↔ AB↔ AB*) that fit the best for full-
length p47phox, ka1, kd1, kforward, and kbackward constants were determined by global fitting. The dissociation constant KDwas determined from the (kd1/ka1)/(1 +
kforward/kbackward) ratio. The heterogeneous ligand model accounts for two different binding sites on the immobilized PCNA, and the corresponding two kinetic
values were calculated. For 1:1 Langmuir and heterogeneous ligand models, the equilibrium dissociation constant is calculated by KD = kd/ka. The data
presented were obtained with a statistic χ2 value <2. Rac2, p40phox, and p67phox were also tested for their interaction with PCNA. Binding of Rac2 (0.51–8,
2 µM) to PCNA was measured and evaluated as reported below (χ2 value 0.6). NA, not applicable; ND, the very low binding signal detected for p47 83–110,
63–90, and 46–67 peptides did not allow evaluation of kinetic data.
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(Fig. 4 G). Notably, T2AA inhibited p47phox translocation to
the membrane during activation without inhibiting its phos-
phorylation. Consistent with a direct interaction between
p47phox and PCNA, we observed that PCNA and p47phox colo-
calized in cytosol in unstimulated neutrophils by confocal mi-
croscopy analysis after indirect immunofluorescence labeling
(Fig. 5 A). Using Duolink technology, a proximity ligation assay,
we provided evidence that PCNA and p47phox are in close
proximity within the cytosol of resting neutrophils (Fig. 5 B). In
contrast, p47phox and rac2, two cytosolic proteins known to
localize in separate cytosolic complexes in resting neutrophils,
did not demonstrate proximity, supporting the specificity of this
technology. Interestingly, PCNA and p47phox proximity was
strongly decreased after PMA activation. Notably, immunopre-
cipitation of PCNA in the cytosol of resting neutrophils showed
that it coimmunoprecipitated with p47phox (Fig. 5 C). However,
the amount of p47phox associated with PCNA was strongly de-
creased after PMA or f-MLF stimulation. Taken together, our
results suggested that PCNA associates with p47phox in cytosol
of resting neutrophils and facilitates NADPH oxidase assembly.
The association is disrupted after activation, although PCNA
could translocate to the plasma membrane. Importantly, T2AA
did not inhibit other antipathogen functions such as
f-MLF–induced degranulation, C5a- or f-MLF–induced chemo-
taxis, and Escherichia coli phagocytosis tested in vitro on isolated
neutrophils (Fig. S3).
Destabilization of PCNA scaffold by T2AA inhibits NADPH
oxidase activity in vivo
We next evaluated whether inhibiting the interaction between
PCNA and p47phox using T2AA would inhibit NADPH oxidase
activity in vivo in inflammatory neutrophils during zymosan-
induced peritonitis in mice (Martin et al., 2016). Peritoneal lav-
ages were collected 4 h after zymosan injection, and inflammatory
cells including neutrophils and macrophages were analyzed by
FACS. T2AA did not have any significant effect on the total number
of cells (Fig. 6 A) or the cellular composition in the lavage fluid
(Fig. 6, B and C). Peritoneal neutrophils from T2AA-treated mice
showed decreased ex vivo ROS production compared with controls
(Fig. 6 D), thereby confirming our in vitro results on human
neutrophils (Fig. 4 D).We next used in vivo noninvasive imaging of
neutrophil activation using L012-enhanced CL (Kielland et al.,
2009) to demonstrate that T2AA could inhibit NADPH oxidase
in situ. Zymosan-induced peritonitis increased L012-CL in the
peritoneum, and T2AA significantly attenuated this (Fig. 6, E and
F). In our previous study, we had shown that p21/waf1 protein acts
as a specific inhibitor of the PCNA scaffold in inflammatory neu-
trophils (Martin et al., 2016). We further investigated NADPH
oxidase activation in inflammatory neutrophils in p21/waf1−/−
mice. PMA-induced ROS production was significantly increased in
peritoneal lavage neutrophils from p21/waf1−/− mice compared
with neutrophils from WT mice, confirming that binding of p21/
waf1 to PCNA restrainsNADPHoxidase activation (Fig. 6, G andH).
Figure 2. Electron density map of PCNA
crystals associated with the p47phox-106-127
peptide and molecular modeling of the com-
plex PCNA-p47phox PX domain. (A) Diffraction
pattern of PCNA crystals soaked in p47phox-
106-127 peptide solution and snapshot of the
frozen crystal. This experiment was performed
three times with identical results. (B) Residual
(Fobs − Fcalc) electron density map from 3.23-
A˚-resolution crystallographic data. The three
highest peaks of the residual (Fobs − Fcalc) elec-
tron density map (green) are located where PIP-
box–containing peptides interact with PCNA.
The p21-139-160 peptide from PCNA-p21-139-
160 peptide complex structure (PDB entry 1AXC)
in cyan with the four main residues of the PIP-
box highlighted in red. (C and D) Two putative
models of PCNA-p47phox-PX domain complex
based on the crystal structures of human PCNA
(blue) the structure of p21-139-160 peptide
(cyan) bound to PCNA and the p47phox PX do-
main (purple) with the residues 106–127 (gold).
Predicted PIP-box residues are depicted in red.
(C) Model based on the putative PIP-box of the
p47phox-106-127 peptide whose conformation
has been modified to fit the p21 peptide struc-
ture. (D) Model based on the structural homol-
ogy between the helix turn of p47phox-122-126
and of the p21-PIP-box.
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Figure 3. PCNA controls ROS production in differentiated PLB985 cells. (A) Representative experiment out of 10 showing the detection of cytosolic PCNA
by immunofluorescence in DMF-differentiated PLB985 cells. The scale bars correspond to 10 µm, magnification 63×. (B) Kinetic analysis of luminol-CL in DMF-
differentiated PLB985 cells transfected with a control (pCT) or with a PCNA-coding plasmid stimulated or not (resting) with PMA or OZ. (C) CL peaks cor-
responding to B were expressed as mean ± SEM of four independent experiments performed in duplicate. (D) FACS plots of DCF-mediated fluorescence in
PLB985-overexpressing PCNA or a nuclear form of PCNA (PCNA-NLS) versus control (pCT). Representative experiment before (–) and after (+) PMA out of four
sets of independent experiments. (E)Quantification of DCF-MFI. Data are mean ± SEM (n = 10 for PCNAWT and CT, n = 4 for PCNANLS). (F–H) Effect of PCNA
siRNA on NADPH oxidase activation. (F) Western blot analysis of PCNA and actin expression after siRNA-PCNA treatment compared with siRNA-CT (upper
panels) and quantification of PCNA/β-actin ratio expressed as mean ± SEM of four independent experiments performed in duplicate (lower panel). **, P < 0.01,
Mann–Whitney U test. (G) Kinetic analysis of luminol-CL of DMF-differentiated PLB985 cells stimulated with PMA or OZ compared with resting. (H) CL peaks
corresponding to G expressed as mean ± SEM of four independent experiments performed in duplicate. (I–K) Effect of p21/Waf1 expression on NADPH oxidase
activation. (I)Western blot analysis of p21/waf1, PCNA, and actin expression (upper panel) and quantification of PCNA/β-actin ratio expressed as mean ± SEM
of three independent experiments performed in duplicate (lower panel). *, P < 0.01, Mann–Whitney U test. (J) Kinetic analysis of luminol-CL of DMF-
differentiated PLB985 cells transfected with a p21/waf1-coding plasmid or a control plasmid (pCT) and stimulated with PMA or OZ. (K) CL peaks corre-
sponding to J expressed as mean ± SEM of eight independent experiments performed in duplicate. ANOVA test was performed (C, E, H, and K): *, P < 0.05; **,
P < 0.01; ***, P < 0.001.
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As we previously reported that PCNA inhibition by the p21
peptide promotes neutrophil apoptosis, we examined whether
T2AA could also affect neutrophil survival. Indeed, T2AA did not
induce ex vivo apoptosis in resting bone marrow neutrophils but
induced dose-dependent apoptosis in inflammatory neutrophils
isolated from peritoneal lavages (Fig. S4 A). Analysis of neu-
trophils from WT and p47phox−/− mice (Kasahara et al., 1997)
showed that this proapoptotic effect of T2AA on inflammatory
neutrophils was not dependent on the presence of p47phox (Fig.
S4 B). From this set of data, we conclude that T2AA triggered
apoptosis preferentially in neutrophils at the inflammatory site
without affecting their survival in bone marrow.
T2AA exerts a potent antiinflammatory effect in
TNBS-induced colitis
As T2AA inhibited ROS production in inflammatory neutrophils,
we investigated whether it could exert an antiinflammatory
effect in TNBS-induced colitis (Wallace et al., 1989), as this
Figure 4. Inhibition of NADPH oxidase activation by targeting the interdomain-connecting loop of PCNA. (A–C) Effect of PCNA inhibitors on NADPH oxidase
activation in a cell-free system. (A) Typical experiment representative of three independent experiments performed in different blood donors showing superoxide
anion production by cytosols and membranes purified from human neutrophils and stimulated by the addition of Li-SDS (S). No superoxide anion was observed in
resting (R) or in the presence of SOD or DPI. Results are expressed as nanomoles of O2−/min/7 × 106 cell membrane equivalent. (B and C) Effect of p21-peptide (B)
or T2AA (C) on superoxide anion production in the cell-free system described in A. Results are ratio of superoxide anion production to untreated positive control.
Data are mean ± SEM for p21-peptide (n = 3; *, P < 0.05, paired Student’s t test) and for T2AA (n = 2). (D) Inhibitory effect of T2AA on NADPH oxidase activation in
neutrophils stimulated with PMA (n = 4), f-MLF (n = 7), or OZ (n = 10). NADPH oxidase activation was evaluated by luminol-CL expressed as ratio to the untreated
stimulated cells. The data are mean ± SEM of the indicated number of independent experiments performed in duplicate (*, P < 0.05; **, P < 0.01; ***, P < 0.001,
ANOVA). (E and F) Representative kinetic analysis of luminol-CL in neutrophils stimulated with f-MLF (E) or PMA (F) compared with resting in the presence or
absence of T2AA (1–10 µM). (G) Effect of T2AA on membrane translocation of PCNA and p47phox. Neutrophils pretreated with or without T2AA for 1 h were
stimulated with PMA. Proteins (PCNA, p47phox, phospho-p47phox, and p22phox) contained in the membrane (memb) or the cytosolic (cyto) fractions were an-
alyzed by Western blot. This experiment is representative of three independent experiments performed in different blood donors yielding the same results.
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model is dependent on early massive recruitment of neutrophils
(Krimi et al., 2008). Mice received two doses of T2AA or vehicle
by intraperitoneal injection after TNBS treatment. The increase
in colonic weight/length ratio induced by TNBS, a macroscopic
indicator of inflammation, was significantly decreased in the
presence of T2AA (Fig. 7 A). These data were supported by the
lower Wallace score in T2AA-treated mice, reflecting less ex-
tensive inflammatory lesions, with a mean percentage of pro-
tection of 50.9 ± 8.8% (Fig. 7 B). Histological analysis confirmed
that TNBS induced strong acute colonic inflammation and ne-
crosis, with extensive ulceration in untreated animals (Fig. 7 D).
The colons of T2AA-treated mice displayed less ulceration and
more advanced healing of the eroded surface. Reepithelization
and regeneration of colonic mucosa were illustrated respectively
by colonization of the ulcer surface by epithelial cells and by
mucosal repair of neighboring ulceration with gland hyperplasia
and numerous mitotic cells. The T2AA beneficial effect was
demonstrated by reduction in the Ameho score (Ameho et al.,
1997), reflecting less-severe histological tissue damage (Fig. 7 C).
To evaluate tissue oxidative stress, we assessed the presence of
myeloperoxidase (MPO), the enzyme responsible for the gen-
eration of chlorinated oxidants by active neutrophils in the
colon. Notably, MPO immunohistochemical staining was
strongly decreased in the colonic epithelium of T2AA-TNBS–
versus TNBS-treated mice, demonstrating a reduced number of
neutrophils present in T2AA-TNBS colon (Fig. 7 D). We also
evaluated in vivo ROS-mediated tissue damage by measuring
malondialdehyde (MDA), a product of lipid peroxidation, in
colon homogenates (Fig. 7 E). Our results show a significant
decrease in MDA concentrations in tissues from T2AA-treated
mice compared with untreated mice, in agreement with de-
creased MPO content. Using the in vivo L012-based imaging
method, we confirmed that neutrophil NADPH oxidase was ac-
tivated in TNBS-induced colitis and that T2AA significantly
decreased L012-CL, indicative of a neutrophil-targeted antiin-
flammatory effect (Fig. 7, F and G). Finally, neutrophil depletion
was used to further ascertain that T2AA targeted activated in-
flammatory neutrophils. Neutrophil depletion using anti-Ly6G
mAb (Coffelt et al., 2015; Fig. 8 A) resulted in a drastic loss of
neutrophils in both blood and bone marrow compared with
control IgG-treated mice (Fig. 8 B). Neutrophil depletion in-
duced a significant decreased severity of colitis in the absence
of T2AA as evidenced by the macroscopic analysis quantified
by the Wallace score (Fig. 8 C). Notably, while T2AA exerted a
Figure 5. Colocalization and coimmunopre-
cipitation of PCNA and p47phox in human
neutrophils. (A) Colocalization of PCNA and
p47phox shown by indirect immunofluorescence
using a polyclonal rabbit anti-PCNA and a mAb
anti-p47phox, respectively. (B) Colocalization of
PCNA and p47phox using the Duolink technol-
ogy. The upper panels show negative controls
using a single antibody. The lower panels show
the fluorescence in the presence of two anti-
bodies: p47phox and rac2; p47phox and PCNA in
the absence or in the presence of PMA. Hoechst
was used for nuclear staining. A and B show
representative experiments of three yielding the
same results. Fluorescence was analyzed by
confocal microscopy. In A and B, the scale
bars correspond to 10 µm, magnification 63×.
(C) Western blot analysis of coimmunoprecipi-
tation between PCNA and p47phox in cytosol
(CYT) of neutrophils without stimulation or after
activation with f-MLF or PMA. Unbound material
in the exclusion fraction (EX) and bound im-
munoprecipitated proteins recovered in the
elution fraction (EL) were analyzed by Western
blot analysis as described in Materials and
methods. This experiment is representative of
three independent experiments performed in
different blood donors yielding the same results.
MW, molecular weight.
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significant antiinflammatory effect in IgG-treated mice, no
effect of T2AA was observed in anti-Ly6G–treated mice.
Histological evaluation and immunolabeling of neutrophils
confirmed the strong decrease in neutrophils in the colon of
anti-Ly6G–depleted and TNBS-treated mice (Fig. 8 E). Im-
portantly, no beneficial effect of T2AA on colon inflammation
assessed by neutrophil immunolabeling was observed in
neutrophil-depleted mice, albeit with a lower baseline level
of disease activity (Fig. 8 E). These new data show that the
acute inflammation observed in TNBS-induced colitis as well
as the antiinflammatory effect of T2AA are both dependent
on the presence of neutrophils.
Discussion
To effectively limit neutrophil-mediated tissue inflammation
and damage, therapeutic strategies should ideally target neu-
trophil release of toxic mediators such as excessive ROS while
promoting neutrophil apoptosis and subsequent clearance.
Therapies should avoid excessive impairment of neutrophil
bone marrow production to limit immunosuppressive con-
sequences. In the current study, we have uncovered a new role
of cytosolic PCNA in the regulation of NADPH oxidase activity
and highlighted the therapeutic potential of targeting PCNA.
The spatial separation of the NADPH oxidase components
between cytosol and membrane and their interaction in com-
plexes ensures that the enzyme is dormant in resting cells
(Boussetta et al., 2010). In this setting, PCNA binds to the
p47phox within the cytosol to restrain NADPH oxidase assembly
and activation. Conversely, upon stimulation, PCNA bound to
p47phox translocates to the membrane to facilitate NADPH as-
sembly. Inhibiting PCNA prevents translocation without inter-
fering with p47phox phosphorylation, thereby acting as a novel
and unexpected regulator of neutrophil activation. It is note-
worthy that, while almost all p67phox and p40phox are in a
complex together with p47phox, excess p47phox can be found
free of the other cytosolic proteins (Iyer et al., 1994; Park et al.,
1994). This unbound p47phox has been shown to interact with
Figure 6. Destabilization of PCNA scaffold
inhibits NADPH oxidase activity in vivo. (A–C)
FACS analysis of cells in the peritoneal lavage 4 h
after zymosan injection in mice treated with or
without T2AA. Two independent sets of experi-
ments were performed with a total of eight mice
per group. (A) Total cell count. (B) Number of
macrophages (F4/80+). (C) Number of neu-
trophils (Ly6G+). (D) Effect of T2AA on ex vivo
neutrophil NADPH oxidase activity measured by
luminol-CL in peritoneal neutrophils stimulated
or not with PMA. The data are CL peaks ex-
pressed as mean ± SEM (n = 8). **, P < 0.01,
ANOVA. (E and F) Inhibitory effect of T2AA on
in vivo ROS production evaluated by L012-CL
during zymosan-induced peritonitis. (E) Repre-
sentative imaging of ROS production in individ-
ual mice. The pseudocolor heat maps represent
photons/s/cm2/steradian. (F) Quantification of
in vivo L012-CL in mice. The data are CL peaks
expressed as mean ± SEM from five to six
mice per group in two independent experiments;
*, P < 0.05; ***, P < 0.001, ANOVA.
(G and H) Ex vivo neutrophil NADPH oxidase ac-
tivity measured by luminol-CL in neutrophils from
WT or p21−/− mice isolated from the peritoneal
lavage 4 h after zymosan injection stimulated or
not with PMA (as in D). (G) Representative kinetic
analysis of NADPH oxidase activation in neu-
trophils from WT compared with p21−/− mice.
(H) The data are CL peaks expressed as mean ±
SEM (from six mice per group in two independent
experiments; *, P < 0.05, ANOVA).
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other cytosolic proteins including protein kinase C (Reeves et al.,
1999) and phospholipase A2 (Shmelzer et al., 2008) and may be
associated with PCNA. Other proteins identified as PCNA part-
ners include cytoskeletal proteins, suggesting that this complex
can facilitate the assembly of active NADPH oxidase complex at
the membrane. Moreover, PCNA association with glycolysis
enzymes, as previously shown in leukemic cells resistant to
chemotherapy (Ohayon et al., 2016), strongly suggests that
PCNA could be a link between survival, ROS production, and
metabolism (Baillet et al., 2017).
We further demonstrated that PCNA binds to the PX domain of
p47phox, in particular the region mapping the 106–127 residues
Figure 7. Antiinflammatory effect of T2AA on TNBS-induced colitis. (A and B)Macroscopic changes following TNBS treatment are represented by colon
weight/length ratio (A) and Wallace score (B) in the respective histograms. (C) Ameho score representative of histological lesions is shown in the histogram.
The data (A–C) are mean ± SEM (**, P < 0.01; ***, P < 0.001, ANOVA) from six to eight mice per group in two independent experiments. (D) Photomicrographs
are representative of H&E-stained slides (upper panels) and of MPO immunohistochemical labeling (lower panels) of paraffin-embedded colonic tissues
recovered from controls, TNBS alone, and TNBS and T2AA. The scale bars correspond to 20 µm, magnification 200×. RG, regeneration; RE, reepithelization.
(E) Colorimetric measurement of MDA in colon. The data are mean ± SEM (n = 6); **, P < 0.01, ANOVA. (F and G) Inhibitory effect of T2AA on in vivo ROS
production measured by L012-CL in TNBS-induced colitis mice. (F) Representative imaging of ROS production in individual mice with untreated TNBS-induced
colitis (right panel) or T2AA-treated TNBS-induced colitis (left panel). This representative experiment shows the pseudocolor heat map representing photons/
s/cm2/steradian. (G) Quantification of in vivo L012-CL from three to four mice per group using the percentages of L012-CL variation between 24 and 48 h. The
data are expressed as mean ± SEM (*, P < 0.05, nonparametric Wilcoxon test).
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involved in lipid binding. This is consistent with the notion that
PCNA inhibits p47phox binding to the membrane in the resting
state. Indeed the crystal structure of the isolated PX domain si-
multaneously bound to phosphatidylinositol 3,4-bisphosphate and
phosphatidic acid revealed that the two lipids bind to two basic
pockets (Karathanassis et al., 2002; El-Benna et al., 2009). This
study further showed that a point mutation of the second SH3
domain or p47phox phosphorylation induced a transition from a
closed to an open conformation that binds membranes through the
PX domain (Marcoux et al., 2010). Our structural analysis using
both crystallography and SPR techniques allows us to propose two
plausible molecular models for the physical association between
the interdomain-connecting loop domain of PCNA and the PX
domain of p47phox. Interestingly, the p47phox 106–127 peptide
that we have identified as the PCNA-interacting site in the PX
domain has been previously reported to strongly inhibit NADPH
oxidase activation in a cell-free system by using a peptide-walking
technique to map p47phox functional domains (Morozov et al.,
1998), confirming that this p47phox sequence indeed has a func-
tional role in the control of NOX2 activation. Because PCNA is a
trimer, it can potentially bind up to three PIP-motif–containing
proteins at the same time (Boehm and Washington, 2016). Al-
though the interdomain-connecting loop of PCNA can bind nu-
merous PIP-box–containing proteins, other domains of PCNA are
involved in the binding with partner proteins including p47phox,
thereby increasing the diversity of interacting partners that PCNA
can accommodate to orchestrate complex biological processes.
We have previously reported that the PCNA scaffold is dy-
namic and is adapted to the inflammatory state of the cell
(Martin et al., 2016). Indeed, PCNA binding to procaspases and to
p47phox has important consequences for cell survival and
NADPH oxidase activation, respectively. Pertinently, p47phox-
PCNA association by maintaining NOX2 in a resting state con-
tributes to neutrophil survival. Nonetheless, PCNA–p47phox
interaction is not essential for PCNA anti-apoptotic activity,
since T2AA triggers apoptosis in inflammatory neutrophils in
both WT and p47phox−/− mice.
Our study demonstrated for the first time that interfering with
PCNA scaffold could be the basis of antioxidant and proresolution
therapy in neutrophil-induced inflammation. A hallmark of
Figure 8. Absence of T2AA antiinflammatory effect in TNBS-induced colitis following neutrophil depletion. (A) Experimental protocol of colitis after
neutrophil depletion using anti-Ly6G mAb. (B and C) Flow cytometry quantification of neutrophils in blood (left panel) and in bone marrow (right panel) in
control (IgG) and neutrophil-depleted (Ly6G) mice. (C)Macroscopic changes following TNBS treatment measured by Wallace score. The data are mean ± SEM
(ANOVA). (D) Representative photomicrographs of neutrophil immunostaining of colonic tissues with the neutrophil marker recovered from control (IgG)
and neutrophil-depleted mice (Ly6G) treated with TNBS alone or TNBS combined with T2AA. The scale bars correspond to 20 µm, magnification 200×.
(E) Quantification of neutrophil immunostaining as described in Materials and methods. In B, C, and E, the data are mean ± SEM. Two independent sets
of experiments were performed with a total of eight mice per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001, ANOVA.
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inflammatory bowel diseases including Crohn’s disease and ulcer-
ative colitis is excessive neutrophil accumulation in the colon, re-
sulting in the release of toxic proteases and ROS (Parkos, 2016).
Excess neutrophil-derived ROS participate in tissue damage in
several inflammatory diseases, so inhibition of NADPH oxidase
activation could represent a relevant therapeutic strategy (Lambeth
et al., 2008).
The role of ROS in inflammation is complex, as they play a role
in tissue damage as well as a positive role in the resolution of in-
flammation (Nathan and Cunningham-Bussel, 2013). Under certain
circumstances, ROSmay be beneficial in promotingwound healing,
and NADPH oxidase defects in patients with chronic granuloma-
tous disease (Segal et al., 2011) and in animal models (Morgenstern
et al., 1997) lead to aberrant inflammation. Chemical NADPH oxi-
dase inhibitors such as apocynin have antiinflammatory effects in
arthritis models (’t Hart et al., 1990) and reduce ethanol-induced
liver inflammation in mice (Gustot et al., 2006). Disrupting the
gp91phox–p47phox interaction using a peptide inhibits NADPH
oxidase (Rey et al., 2001). Likewise, targeting PCNA could be a
strategy to dampen this neutrophil contribution to inflammation. In
a therapeutic setting, chemical targeting of NADPH oxidase protein
interaction potentially allows temporary and dose-dependent re-
duction of ROS, favoring the dampening of inflammation compared
with the complete loss of NADPH oxidase function. It should be
noted that in the current study along with the antiinflammatory
effect, short T2AA treatment not only did not interfere with epi-
thelial cell proliferation in TNBS-induced colitis, but it significantly
enhanced epithelium regeneration. Our data strongly suggest that
T2AA in this setting primarily targeted inflammatory neutrophils
and did not demonstrate a negative effect on regenerating tissue at
the site of inflammation. Here we show that T2AA also reduced
neutrophil survival as an added antiinflammatory mechanism to
limit neutrophil-mediated tissue damage, as previously demon-
strated for roscovitine, a cyclin-dependent kinase inhibitor (Rossi
et al., 2006). Down-regulating neutrophil activation and promoting
neutrophil apoptosis represent important mechanisms in inflam-
mation resolution (Serhan et al., 2007; Jones et al., 2016). None-
theless, evaluation of the therapeutic value of T2AA as an
antiinflammatory drug will require investigation of its effects on
othermodels of inflammation. Notably, T2AA also did not adversely
affect neutrophil progenitor survival. As previously mentioned,
chemical strategies are reversible, and moderate reduction of
NADPH oxidase function may provide antiinflammatory effects
without compromising antipathogen function.
Cytosolic PCNA acts as a molecular “organizer” of neutrophil
effector functions, coordinating apoptosis and governing neu-
trophil activation. Neutrophils represent a unique cellular model
to elucidate the functions of cytosolic PCNA, and these findings
could lead to the concept of molecular linkage of cell survival,
oxidant-related processes, and metabolism that is relevant to the
control of inflammation.
Materials and methods
Isolation of human neutrophils
Neutrophils were obtained from EDTA-anticoagulated blood
from healthy donors in agreement with Etablissement Francais du
Sang guidelines. Each donor gave written informed consent to
participate in this study, which was approved by the Institut
National de la Sante´ et de la Recherche Me´dicale Institutional
Review Board (Paris, France). The study was conducted according
to the Declaration of Helsinki. Neutrophils were isolated in LPS-
free conditions by dextran sedimentation and Ficoll centrifuga-
tion as previously described (Witko-Sarsat et al., 2010).
Identification of PCNA partners by MS
Control IgG or rabbit polyclonal anti-PCNAAb5 antibody (20 µg)
was cross-linked to 50 µl of protein G Sepharose beads (Pierce)
using 100 µl dimethyl pimelimidate (20 mM; Pierce) in cross-
linking buffer (200 mM carbonate buffer, pH 9) for 30 min
according to the manufacturer’s instructions and as previously
described (Borregaard et al., 1983; Ohayon et al., 2016). Proteins
(200 µg) from human neutrophil cytosols were obtained by
nitrogen cavitation to prevent granule rupture, preserving cy-
tosolic proteins from artifactual proteolysis as previously de-
scribed (Witko-Sarsat et al., 2010). Neutrophil cytosol was added
to Sepharose beads cross-linked with anti-PCNA antibody and
incubated for 2 h at 4°C. Proteins bound to the beads were re-
covered after extensive washing and were denatured at 95°C in
reducing conditions with Laemmli buffer. Supernatants were
loaded onto an SDS-PAGE gel for a short migration, and proteins
were trypsin-digested in-gel. For liquid chromatography/MS
protein analysis, peptides were concentrated, washed, and an-
alyzed using a reverse-phase C18 column on a u3000 nanoHPLC
connected to a Linear Trap Quadrupole-Orbitrap mass spec-
trometer (Thermo Fisher Scientific). LTQ MS/MS collision-
induced dissociation spectra were acquired from the ≤20 most
abundant ions detected in the Orbitrap MS scan. Protein
identifications were performed with the Proteome discoverer
1.3 (Thermo Fisher Scientific) and with Mascot (http://www.
matrixscience.com). Separate analysis was conducted and
compared using MyPROMS software. The proteomic analysis
was performed in the Proteomics 3P5 facility of the Cochin
Institute–Paris Descartes University in Paris.
SPR
PCNA was expressed in E. coli and purified as previously de-
scribed (Desplancq et al., 2016), except that size-exclusion
chromatography was performed in 20 mM Tris, pH 7.5, 0.1 M
NaCl, and 0.1 mM 2-ME. Recombinant human p47phox,
p67phox, and Rac2 were produced as previously described (Raad
et al., 2009). Recombinant p40phox expressed in E. coli was
purchased from Creative Biomart. To generate the PX domain of
p47phox, a truncated p47phox (residues 2–132) was produced in
E. coli using the pGEX plasmid (generous gift of Dr. Yaffe,
Massachusetts Institute of Technology, Cambridge, MA). SDS-
PAGE analysis of purified recombinant proteins expressed in
E. coli confirmed the purity and the expected molecular mass of
each protein: PCNA (36 kD), p47phox (47 kD), p47phoxPX (14
kD), p67phox (67 kD), and Rac2 (22 kD). Interactions between
PCNA and cytosolic proteins of the NADPH oxidase complex
were studied by SPR on a Biacore T200 or a Biacore 3000 system
(GE Healthcare) designed to calculate affinity and kinetic pa-
rameters. PCNA was covalently immobilized on a dextran layer
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sensor chip (CM5) with 10 mMHepes and 150 mMNaCl, pH 7.4.
The recombinant proteins p47phox, p47phox PX domain,
p67phox, p40phox, and Rac2 at the indicated concentrations
(25–400 nM) were used as analytes in a running buffer (50 mM
Tris and 150 mM NaCl, pH 7.4) and were injected at 20 µl/min
for 120 s over immobilized PCNA (4,100 response units [RU])
and over a control flow cell submitted to the coupling steps
without PCNA. Binding experiments were performed at 25°C.
In all experiments, the specific binding signal was obtained by
subtracting the background signal.
For global fitting of the full-length p47phox
We used kinetic titration on the Biacore T200 system, referred
to as single-cycle kinetics, to collect binding data for kinetic
analysis. This method involves sequential injections of several
analyte concentrations over the ligand immobilized on the
sensor chip surface without a regeneration step between suc-
cessive injections. The association (ka) and dissociation (kd) rate
constants and KD were calculated using BIAevaluation software.
For peptides and p47phox PX domain–PCNA interactions
The running buffer was PBS, pH 7.4 (peptides), or 50 mM Tris
and 150 mM NaCl, pH 7.4 (p47phox PX), and the surface was
regenerated with pulses of 0.5 mM glycine, pH 3. The immo-
bilization level for PCNA was 4,300 RU. Association phases ran
for 120 s, and dissociation phases ran for 120 s on a Biacore 3000
system.
Inhibition assays
The phospholipid phosphatidylinositol (3,4,5)-trisphosphate
(PIP3,4,5; Sigma-Aldrich), which specifically binds to the PX
domain of p47phox, was used to inhibit the binding of p47phox
to PCNA at the indicated concentrations ranging from 4 to
80 µM. The dose-dependent inhibition by the phospholipid
PIP3,4,5 was performed on 4,100 RU of immobilized PCNA using
the Biacore T200 apparatus. The solution containing p47phox
(200 nM) was incubated for 10min at 25°C with lipids at various
concentrations before injection. The signal was measured at the
end of the association phase (120 s) and compared with those
obtained in the absence of lipids.
Inhibition studies using p21 peptide and p47phox peptides
were performed using the Biacore 3000 on 2,600 RU of im-
mobilized PCNA. p47phox (500 nM) samples were coinjected
with peptides at various concentrations, and the association
phase ran for 120 s. Because peptides interact with PCNA, we
evaluated inhibition by measuring the SPR signal at the end of
an extended dissociation phase (380 s), a time point at which
peptides that have a higher dissociation rate than the protein are
completely dissociated and, consequently, at which the signal is
due to P47phox only. Inhibition was then evaluated by com-
paring the remaining signal in the dissociation phase obtained
when peptide and protein were coinjected to those measured
after injection of the protein alone.
Kinetic values determination
Data were analyzed by global fitting to binding models of
both the association and the dissociation phases for several
concentrations simultaneously using BIAevaluation software.
The simplest 1:1 Langmuir binding model was first tested. The
two-state reaction model and heterogeneous ligand model were
used when they significantly increased the statistical goodness-
of-fit as calculated by Biacore software. In the case of P47–PCNA
interaction, the two-state reaction model suggested a possible
conformational change of P47 during interaction. For short
peptides that are supposed to be homogeneous in solution, the
heterogeneous ligand model accounts for the presence of two
sites that bind analyte independently of each other. SPR analysis
was performed at the Structural Biology Institute at the Gre-
noble Instruct–European Research Infrastructure Consortium
facility in Grenoble.
Crystallographic data collection and structure determination
Crystals were obtained using hanging drop vapor-diffusion
technique at 20°C and by mixing 1 µl of PCNA at 4.7 mg/ml
with 1 µl of the crystallization solution in the presence or ab-
sence of p47phox-106-127 peptide (Fig. S1). A search for PCNA
crystallization conditions was based on previously published
conditions and systematic screening using commercial screens.
The best crystals were obtained with a crystallization solution
containing 19–23% PEG 3350, 0.2–0.3 M NaCl, and 0.1 M Tris-
HCl, pH 8.5. Approximately 12 h before crystal freezing,
100–500 µM of p47phox-106-127 peptide was added to the
crystallization drop. 25% glycerol was added to the crystalliza-
tion drop to prevent ice formation, and crystals were fished out
and immediately frozen in liquid nitrogen. Crystallographic data
were collected at −160°C on beamlines BM30-A and ID30-A1 at
the European Synchrotron Radiation Facility in Grenoble,
France. Data processing was performed using the XDS package,
and the PCNA structure was determined by the molecular re-
placement technique using PHASER and the CCP4 suite of pro-
grams. The search model used was the human PCNA (PDB entry
1AXC). The final PCNA model was obtained after several cycles
of manual model building with COOT software and maximum
likelihood refinement using the REFMAC5 program. The
highest-resolution structure was refined against 2.8-A˚ data, but
showed no significant electron density for the soaked peptide.
The structure that showed the largest amount of (Fobs − Fcalc)
residual electron density, located in the vicinity of the
interdomain-connecting loop, was refined at 3.22-A˚ resolution.
No peptide could be reliably refined into this electron, and the
final model accounts for only the trimeric PCNA structure. Data
processing and refinement statistics are presented in Table S1.
Molecular modeling
Molecular modeling was used to propose two possible docking
modes of the p47phox PX domain onto the PCNA. Models are
based on the crystallographic structures of the human PCNA in
complex with p21-141-160 peptide (PDB entry 1AXC) and of the
human p47phox PX domain (PDB entry 1KQ6). For the first
model, the 106–127 PX segment was manually modified with
COOT software to have the PX 114–118 region adopting the same
conformation as the 147–151 segment in p21 peptide, when bound
to PCNA, with an orientation compatible with docking onto
PCNA. The stereochemistry of the 106–127 PX segment was
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optimized by the refinement procedure implemented in COOT.
The second model was built by simply superposing the PX
122–126 helix turn onto the 147–151 segment in p21 peptide, when
bound to PCNA.
Transfection and differentiation of PLB985 cells
PLB985 cell lines were cultured in RPMI supplemented with 10%
FBS, L-glutamine (2 mM), antibiotics (penicillin 100 U/ml and
streptomycin at 100 µg/ml), and Hepes buffer. PLB985 cell
granulocytic differentiation was induced by exposure to 0.5%
DMF for 5 d and was validated by FACS analysis of CD11b ex-
pression, as described previously (De Chiara et al., 2013). For
PCNA overexpression, PLB985 cells were stably transfected with
empty pcDNA3 plasmid (pCT), pcDNA3-PCNA (PCNA), and
pcDNA3-SV40NLS-PCNA (PCNA-NLS; Bouayad et al., 2012) to
generate control PLB985, PLB985 overexpressing PCNAWT, and
PLB985 overexpressing exclusive nuclear PCNA, respectively.
For p21/waf1 overexpression, PLB985 cells were stably trans-
fected with empty PRC-RSV-neo plasmid (Invitrogen) or PRC-
RSV/p21A45R to generate control PLB985, PLB985P21, and
PLB985P21A45R as previously described (Dublet et al., 2005).
Notably, because p21/waf1 is sensitive to degradation by neu-
trophil proteinase 3, we have used themutant p21A45R, which is
resistant to serine proteases and is more stable in the current
study (Martin et al., 2016). Western blot analysis using anti-
PCNA (rabbit polyclonal Ab5) or p21/waf1 (rabbit polyclonal
Santa Cruz) on PLB985 lysate was used to assess the expression
of PCNA and p21/waf1, respectively. PCNA, p21/waf1, and actin
bands were quantified and normalized as PCNA/β-actin ratio. Of
note, the PCNA protein expression was not affected by the ec-
topic expression of p21/waf1.
For PCNA siRNA experiments, PLB985 cells were treated
with DMF to induce granulocytic differentiation and transfected
with 1 µM siRNA (Applied Biosystems) twice at a 24-h interval
(day 4 and day 5 after DMF treatment) using the Amaxa system
(Lonza), according to the manufacturer’s instructions. In brief,
2 × 106 cells were resuspended in 100 µl of cell line solution with
1 µg of plasmid. The cells were then electroporated and trans-
ferred to culture plates. Transfected cells were cloned and
selected based on their resistance to 1 mg/ml neomycin. FITC-
conjugated control siRNA, used to detect intracellular siRNA by
FACS and to monitor transfection efficiency, showed that the
fluorescent siRNA was taken up in >90% of the PLB985 cells.
Western blot analysis using anti-PCNA (rabbit polyclonal Ab5)
on PLB985 lysate was used to validate the efficacy of PCNA
siRNA in decreasing the expression of PCNA protein. PCNA and
actin bands were quantified and normalized as PCNA/β-actin
ratio. Flow cytometry analysis was performed at Cytometry and
Immunobiology at the Cochin Institute in Paris.
Measurement of NADPH oxidase activation and ROS
production in cells
Intracellular ROS accumulation in PLB985 cells was measured
using DCF-DA (Sigma-Aldrich), a green fluorescent probe. DMF-
differentiated PLB985 cells (0.5 × 10−6) were prestained at 37°C
for 15 min with 0.5 µM of H2DCF-DA, which is rapidly oxidized
to highly fluorescent DCF in the presence of intracellular H2O2.
Cells were washed and stimulated for 45 min with or without
PMA (1 µg/ml) at 37°C. DCF fluorescence was measured by a
FACS BD Accuri C6 (BD Biosciences).
ROS production was measured by luminol CL: isolated neu-
trophils (1 × 105) were suspended in 0.1 ml of HBSS containing
10 µM luminol and pretreated with or without T2AA (Inoue
et al., 2014; generous gift of Prof. Naoki Fujii, St. Jude Child-
ren’s ResearchHospital, Memphis, TN) at 10, 25, or 50 µM for 1 h
at 37°C. Neutrophils were then stimulated with or without PMA
(0.1 µg/ml), OZ (1 mg/ml), or f-MLF (1 µM). CL was recorded at
37°C in a luminometer (Berthold-Biolumat LB937) in duplicate
over 40 min and expressed as integrated total counts. Mea-
surement of NADPH oxidase activation in PLB985 transfected
cells was performed with the same protocol except that they
were adjusted at 0.5 × 10−6 cells/ml and stimulated with PMA at
1 µg/ml or OZ at 0.5 mg/ml. Luminescence was recorded using
the TriStar LB 941 Multimode Microplate Reader (Berthold) and
expressed as relative light units.
Measurement of NADPH oxidase activation using cell-free
system experiments
NADPH oxidase activity was measured in a cell-free system
usingmembrane and cytosolic fractions of resting neutrophils as
previously described (Molshanski-Mor et al., 2007). The reac-
tion mixture contained 1 mM ATP, 1.25 mM EGTA, 50 µM
guanosine 59-(γ-thio)triphosphate (Sigma-Aldrich), and 7 × 106
cell membrane equivalent. When indicated, the p21 peptide or
T2AA was preincubated for 10 min at 37°C at the indicated
concentration. Cells were then stimulated with (S) or without
(R) 100 µM Li-SDS (Fluka) for 5 min at 37°C before starting the
reaction. The reactionwas then initiated with 200 µM β-NADPH
(Sigma-Aldrich) and cytochrome c (1 mg/ml). Absorbance at 550
nmwas read immediately, and superoxide anion production was
calculated using an extinction coefficient of 21.1 mM−1 cm−1 for
reduced ferricytochrome c. The specificity of the reaction was
evaluated by adding 20 µM DPI or 30 U/ml SOD. Results are
expressed as nanomoles of O2−/min/7 × 106 cell membrane
equivalent.
Translocation of p47phox from the cytosol to the
neutrophil membrane
After isolation from whole blood, 100 × 106 neutrophils were
resuspended in 5 ml of HBSS+/+ and incubated with or without
T2AA (25 or 50 µM) at 37°C for 1 h. Neutrophils were then
stimulated with PMA (200 ng/ml) for 8 min while the mixture
was gently shaken. Ice-cold buffer was added, and cells were
pelleted by centrifugation at 400 g for 8 min at 4°C. The pellets
were resuspended in relaxation buffer containing 1 mM ATP,
1 mM EGTA, 0.5 mM PMSF, 25 nM Calyculin, and 5 µg/ml of
aprotinin, leupeptin, and pepstatin. The cells were then dis-
rupted by sonication (twice for 10 s each time) at 4°C and
centrifuged at 400 g for 8 min. The postnuclear supernatant was
loaded onto a discontinuous sucrose gradient (35 and 15% su-
crose) diluted in relaxation buffer and centrifuged for 45 min
at 150,000 g. The cytosolic and membrane fractions (in the
upper and the intermediate layers, respectively) were col-
lected. Proteins were analyzed by Western blot analysis using
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anti-p47phox (BD Transduction Laboratories), anti-p22phox
(Santa Cruz), anti-phospho-p47phox, and anti-PCNA (clone
PC10; Santa Cruz) mouse mAbs. Expression of p22phox and total
p47phox served as a loading control in membrane fraction and
cytosolic fraction, respectively.
Analysis of in situ interaction between PCNA and p47phox
using indirect immunofluorescence and the Duolink system
Neutrophils were spotted using round-shaped filter paper on
poly-L-lysine–coated glass slides and allowed to dry in a humid
chamber by gravity sedimentation, then fixed with 2% para-
formaldehyde for 10min, permeabilized with 0.2% Tween 20 for
15 min at 37°C, and blocked with 5% BSA in PBS. Cells were then
incubated overnight at 4°C with a rabbit anti-PCNA polyclonal
antibody (1:200) and mouse anti-p47phox mAb (1:200) diluted
in 1% BSA/PBS. After washing, cells were incubated with Alexa
Fluor 488–conjugated (green) goat anti-rabbit antibody (1:200)
and Alexa Fluor 568–conjugated (red) goat anti-mouse antibody
(1:200) for 1 h at room temperature in the dark. Nuclei were
stained with TO-PRO-3 iodide (Invitrogen). A proximity ligation
assay using the Duolink system was performed on human iso-
lated neutrophils spotted on poly-L-lysine–coated glass slides
according to the manufacturer’s instructions using two primary
antibodies from different species (the rabbit polyclonal anti-
PCNA Ab5, the mAb anti-p47phox [Millipore], or the rabbit
polyclonal anti-rac 2 [Abcam]). When indicated, neutrophils
were treated with PMA (0.1 µg/ml for 10 min) before labeling.
Resting neutrophils treated with anti-p47phox; anti-PCNA an-
tibodies show a cytosolic fluorescence indicative of a colocali-
zation. Hoechst was used for nuclear staining. Stained cells were
examined with a Zeiss LSM510 confocal microscope (63×/1.4
numerical aperture objective), and the images were imported
into an LSM image browser for analysis. The designation
“merge” for indirect immunofluorescence analysis corresponds
to colocalization of PCNA and p47phox. The magnification used
was 63×, and different zoom settings were used. The final
magnification is indicated by the presence of a scale bar for each
experiment.
Coimmunoprecipitation experiments
Human isolated neutrophils (25 × 106/ml per condition) were
stimulated with PMA (0.1 µg/ml) or f-MLF (1 µM) for 1 h at 37°C
with 5% CO2. Neutrophil cytosol was obtained by sonication in a
hypotonic Hepes buffer (50 mM) supplemented with inhibitors
(4 mM PMSF, 20 mM leupeptin, 20 mM pepstatin, 270 mM
orthovanadate, 200 mM EGTA, and 500 mM EDTA) with a So-
niprep 150 Plus sonicator (1 Hz for 10 s). Protein concentration
was measured using the BCA kit (Pierce). Coimmunoprecipita-
tion experiments were performed on cytosol (500 µg of protein)
by adding 7.5 µl rabbit anti-PCNA Ab5 or control rabbit IgG for
15 min at 4°C under rolling. Next, 50 µl of protein A beads were
added and incubated for 30 min at 4°C under rolling and 15
min on ice. The sample was loaded onto a column containing
Sepharose-coated magnetic beads (Miltenyi) prehydrated with a
washing buffer (50 mM Tris, pH 8, 300 mM NaCl, and 1% NP-
40). The column was washed four times with this salt-
containing buffer and five times with a wash buffer (20 mM
Tris, pH 7.5). The sample was eluted from the columnwith 50 µl
5× boiling sample buffer. Cytosol (30 µg of protein) elution and
exclusion samples were analyzed by Western blotting using
anti-p47phox (BD Biosciences; 610354) and PCNA (PC10 mAb)
followed by HRP-conjugated anti-mouse IgG (Nordic Immunol-
ogy; diluted 1:5,000), using the SuperSignal West Pico detection
kit (Pierce) as previously described (Witko-Sarsat et al., 2010).
Mouse models of inflammation
Animal studies were performed in accordance with the Euro-
pean Community Guidelines (authorization number B-75-1394
and C-75-1801). All protocols were approved by Ethics Com-
mittee for Animal Research of Universite´ Paris Descartes
(CEEA34-VWS.074.12) and of Faculte´ Bichat (CEEA-JCM.121).
Zymosan-induced peritonitis in mice
The model of zymosan-induced peritonitis was used to examine
the NADPH oxidase activity in murine inflammatory neu-
trophils. Peritonitis was induced in mice (male C57BL/6J mice,
9–30 wk old; Charles River) by an intraperitoneal injection
of 1 mg of Zymosan A from Saccharomyces cerevisiae (40 mg/kg;
Sigma-Aldrich) in 0.5 ml of sterile PBS as previously described
(Martin et al., 2016). After 4 h, mice were sacrificed by cervical
dislocation, and the peritoneal cavities were washed with 4ml of
PBS. Aliquots of lavage fluids (10 µl) were diluted in Turk’s so-
lution (0.01% crystal violet in 3% acetic acid), and cells were
counted using a Mallassez hemocytometer. Analysis of neu-
trophils or macrophages was performed by flow cytometry after
immunolabeling with anti-Ly6G-FITC (BD Biosciences) and anti-
F4/80–Alexa Fluor 647 (AbD Serotec), respectively. Isolated
neutrophils (1 × 106) from the peritoneal lavage were suspended
in 0.5 ml HBSS+/+ and stimulated with or without PMA (1 µg/
ml), and luminol CLwas recorded by a TriStar LB 941Multimode
Microplate Reader as described above. When indicated,
zymosan-induced peritonitis was performed in p21/Waf1
knockout mice (p21−/−) obtained from the Jackson Laboratory
(B6;129S2-Cdkn1atm1Tyj/J) and housed with their WT littermate
controls (Martin et al., 2016). To evaluate the effect of in vivo
injection of T2AA on oxidative burst in inflammatory neu-
trophils, mice were pretreated with or without T2AA (20mg/kg)
for 30 min and 17 h before the injection of zymosan to trigger
peritonitis.
To evaluate the ex vivo effect of T2AA on the survival of
neutrophils in C57BL/6J WT mice compared with mice lacking
p47phox (p47phox−/− mice [Ncf1m1J]; the Jackson Laboratory),
peritonitis was induced inmice (male and female C57BL/6Jmice,
9–30 wk old) by an intraperitoneal injection of zymosan. After
4 h, mice were sacrificed with isoflurane, and the peritoneal
cavities were washed with 4 ml of PBS. Neutrophils were then
purified using a Ficoll gradient and cultured at 37°C in 5% CO2
for 16 h with or without T2AA (10, 25, or 50 µM). Next, 0.2 × 105
of purified neutrophils in basal state and after overnight
incubation were stained with APC-conjugated mAb anti-Ly6G
(BD Pharmigen; clone 1A8; 4 µg/ml final concentration) and
also FITC-conjugated Annexin-V (Miltenyi Biotec) and 7-
aminoactinomycin D (7-AAD; BD Biosciences) to evaluate the
proportion of neutrophil survival.
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Induction of TNBS-induced colitis in mice
We investigated the therapeutic effect of T2AA in TNBS-induced
colitis in mice as previously described (Krimi et al., 2008). Male
C57BL/6J mice (19–22 g; Janvier Laboratories) were deprived of
food for 24 h before colitis induction. Then mice were anesthe-
tized for 90–120 min for the induction of colitis. They received an
intrarectal administration of TNBS (40 µl, 150mg/kg) dissolved in
a 1:1 mixture of 0.9% NaCl with 100% ethanol. Control mice re-
ceived a 1:1 mixture of 0.9% NaCl with 100% ethanol. After each
rectal administration of TNBS, mice were kept in an inverted
position for 30 s. 6 and 24 h after TNBS injection, mice received an
intraperitoneal injection of T2AA (25 mg/kg) or vehicle solution.
Animals were sacrificed 2 d after TNBS administration. When
indicated, neutrophil depletion was performed using two in-
jections of anti-Ly6G antibody (clone 1A8) as previously described
(Coffelt et al., 2015), 18 h (400 µg/mouse) before and 5 h (100 µg/
mouse) after induction of colitis (Fig. 8 A).
Colic inflammationwas evaluated by the weight and length of
each intestine (anus to cecum). The colons were opened and
examined to evaluate macroscopic lesions according to the
Wallace criteria (Wallace et al., 1989). The Wallace score rates
macroscopic lesions on a scale from 0 to 10 based on features
reflecting inflammation such as hyperemia, thickening of the
bowel, and extent of ulceration. For histological analysis, colon
specimens located 1 cm above the anus were removed to be in-
cluded in paraffin. Several 5-µm paraffin sections were pre-
pared and stained with H&E according to the Ameho criteria
(Ameho et al., 1997). This grading is scaled from 0 to 6 and takes
into account the presence of erosion, ulceration, or necrosis and
the depth and surface of lesions. Immunohistological labeling of
colon sections was also performed with a polyclonal rabbit anti-
MPO (A0398, Dako) and with the neutrophil-specific marker
antibody (rat mAb clone 6A608; Santa Cruz) as previously de-
scribed (Martin et al., 2016). To evaluate the presence of neu-
trophils within the colon, we quantified the immunostaining
obtained with the neutrophil marker (clone 6A608). Slides were
entirely scanned by the Lamina Slide Scanner (PerkinElmer),
and regions of interest were manually defined using Case
Viewer (https://www.3dhistech.com/software-downloads).
Surfaces of tissue regions of interest were determined with
INFORM software (PerkinElmer) by tissue segmentation. Then,
surfaces of neutrophil signal were determined by the “threshold”
command. The ratio between these two surfaces were calculated
to analyze and compare the variations of the immunostained
surfaces percentage. The immunohistochemistry study was
performed at the Histology, Immunostaining, and Laser Micro-
dissection facility at Cochin Institute in Paris.
Noninvasive in vivo imaging of NADPH oxidase activity using
L012-enhanced CL
Measurement of in vivo neutrophil NADPH activation was
performed as previously described (Kielland et al., 2009), with
somemodifications. For the zymosan-induced peritonitis model,
mice were first injected intraperitoneally with 1 mg zymosan to
induce peritonitis, followed by T2AA treatment (25 mg/kg) 4 h
later. To measure in vivo neutrophil NADPH activation, the lu-
minescent probe L012 (Sobioda) was prepared freshly right
before the experiment by dissolving 2 mg L012/ml in sterile PBS
and kept in the dark. L012 was administered at 20 mg/kg by
intraperitoneal injection to the right flank of isofluorane-
anesthetized (1.5–2.5%) mice 6 h after the initial injection of
zymosan. In the model of TNBS-induced colitis, L012 was in-
jected at 24 and 48 h after TNBS treatment to measure in vivo
activity of NADPH oxidase at these time points. Results are
expressed as the variation of L012-CL between 24 and 48 h. For
all the in vivo imaging of NADPH oxidase activity, L012 was
administered to mice that had been under anesthesia for 3 to
4 min, after which mice were placed into the light chamber of
the Photon Imager RT imaging system (BiospaceLab) equipped
with an intensified charge-coupled device camera that allows
real-time recording of emitted photons. The number of photons
produced by L012 during in vivo imaging was collected during
10min. A maximum of five individual mice per acquisition were
positioned supine in the chamber. Regions of interest were
drawn using M3 Vision proprietary software (BiospaceLab).
This software allows quantification of photons emitted over time
in each region of interest with real-time photon collection.
Quantification was performed measuring emitted photons in a
time window corresponding to the plateau of the intensity
curve, for each region of interest. Light emission from the ab-
dominal region of interest was quantified and expressed as
photons/s/cm2/steradian. This study was performed at the
Small Animal Imaging facility at the Cochin Institute in Paris.
Statistical analysis
Statistical analysis was performed using the Statview software
package. Comparisons were made using the Student’s t test,
multicomparison ANOVA, or the Mann–Whitney U test as in-
dicated. Differences were considered significant at P < 0.05.
Accession numbers
The structure factors and coordinates have been deposited in the
PDB under accession nos. 6FCM (PCNA structure at 2.8 A˚) and
6FCN (PCNA structure at 3.22 A˚ in combination with the
p47phox peptide).
Online supplemental material
Fig. S1 is a structural analysis of the association between PCNA
and the p47phox peptides. Fig. S2 shows the effect of PCNA
inhibition on viability in differentiated PLB985 cells or human
neutrophils. Fig. S3 shows the effect of T2AA on degranulation,
chemotaxis, and phagocytosis of E. coli in isolated human neu-
trophils. Fig. S4 shows the effect of T2AA on neutrophil survival
isolated from WT and from p47phox−/− mice. Table S1 shows
crystallographic data collection and refinement statistics.
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